BR112021024300A2 - Formas de sais cristalinas de um inibidor de quinase - Google Patents
Formas de sais cristalinas de um inibidor de quinaseInfo
- Publication number
- BR112021024300A2 BR112021024300A2 BR112021024300A BR112021024300A BR112021024300A2 BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2 BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A BR112021024300 A BR 112021024300A BR 112021024300 A2 BR112021024300 A2 BR 112021024300A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- relates
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical class C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065980 WO2020247019A1 (en) | 2019-06-03 | 2019-12-12 | Crystalline salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024300A2 true BR112021024300A2 (pt) | 2022-01-11 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024300A BR112021024300A2 (pt) | 2019-06-03 | 2019-12-12 | Formas de sais cristalinas de um inibidor de quinase |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (enExample) |
| EP (1) | EP3976587B1 (enExample) |
| JP (1) | JP7579281B2 (enExample) |
| KR (1) | KR102826380B1 (enExample) |
| CN (1) | CN113939503B (enExample) |
| AU (1) | AU2019449809B2 (enExample) |
| BR (1) | BR112021024300A2 (enExample) |
| CA (1) | CA3139148A1 (enExample) |
| CL (1) | CL2021003205A1 (enExample) |
| CO (1) | CO2021017343A2 (enExample) |
| CR (1) | CR20210616A (enExample) |
| DO (1) | DOP2021000236A (enExample) |
| ES (1) | ES3008963T3 (enExample) |
| GE (2) | GEP20247655B (enExample) |
| IL (1) | IL288484A (enExample) |
| MA (1) | MA56001A (enExample) |
| MX (1) | MX2021014773A (enExample) |
| PE (1) | PE20220962A1 (enExample) |
| PH (1) | PH12021553020A1 (enExample) |
| SG (1) | SG11202111978VA (enExample) |
| WO (1) | WO2020247019A1 (enExample) |
| ZA (1) | ZA202108034B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| US20250368606A1 (en) | 2021-12-22 | 2025-12-04 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| MA48776A (fr) * | 2017-05-26 | 2020-04-08 | Exelixis Inc | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553020A1 (en) | 2023-08-23 |
| JP7579281B2 (ja) | 2024-11-07 |
| ES3008963T3 (en) | 2025-03-25 |
| EP3976587A1 (en) | 2022-04-06 |
| EP3976587B1 (en) | 2024-12-04 |
| AU2019449809B2 (en) | 2026-02-05 |
| SG11202111978VA (en) | 2021-11-29 |
| CN113939503A (zh) | 2022-01-14 |
| CN113939503B (zh) | 2024-05-07 |
| IL288484A (en) | 2022-01-01 |
| KR102826380B1 (ko) | 2025-06-26 |
| AU2019449809A1 (en) | 2021-12-16 |
| DOP2021000236A (es) | 2022-04-18 |
| CA3139148A1 (en) | 2020-12-10 |
| GEAP202415849A (en) | 2024-03-11 |
| KR20220016117A (ko) | 2022-02-08 |
| PE20220962A1 (es) | 2022-06-10 |
| US20230052703A1 (en) | 2023-02-16 |
| EP3976587C0 (en) | 2024-12-04 |
| JP2022535072A (ja) | 2022-08-04 |
| MA56001A (fr) | 2022-04-06 |
| WO2020247019A1 (en) | 2020-12-10 |
| CO2021017343A2 (es) | 2022-01-17 |
| GEP20247655B (en) | 2024-08-26 |
| ZA202108034B (en) | 2025-02-26 |
| CR20210616A (es) | 2022-03-22 |
| CL2021003205A1 (es) | 2022-09-30 |
| MX2021014773A (es) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
| EP4631505A3 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| BR112021023765A2 (pt) | Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| BR112018008918A8 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
| BR112013021236A2 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| BR112015022785A2 (pt) | composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt | |
| BR112017002403A2 (pt) | formas de cristais de inibidores de glutaminase | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| MX2024010863A (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2). | |
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante | |
| BR112021023927A2 (pt) | Composto, e, composição farmacêutica | |
| BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
| BR112021024955A2 (pt) | Inibidores de piridila ou pirimidila da quinase mtor | |
| BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
| BR112022015925A2 (pt) | Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos | |
| BR112017020053A2 (pt) | novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo | |
| CR20230223A (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| BR112018071860A2 (pt) | derivados de prostaglandina | |
| BR112021025079A2 (pt) | Composto, uso de um composto, método para o tratamento ou profilaxia de doenças e condições afetadas pela modulação de tmem16a e composição farmacêutica | |
| CY1124087T1 (el) | Παραγωγα πυριδοκιναζολινης χρησιμα ως αναστολεις πρωτεϊνικων κινασων | |
| EA202191653A1 (ru) | Кристаллические формы и солевые формы ингибитора киназы | |
| BR112021012817A2 (pt) | Tratamento da síndrome de pitt-hopkins | |
| CO2020014069A2 (es) | Sales de meglumina de tienopirimidinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |